Innovent Biologics showcases promising preclinical data at AACR 2024
In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and metabolic diseases, autoimmune disorders, ophthalmology, and other major diseases, has announced the presentation of preclinical data on multiple novel bispecific antibodies and antibody-drug conjugates (ADCs) from its oncology pipeline at […]